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Abstract
Background: We previously reported that intrathecal injection of lysophosphatidylcholine (LPC)
induced neuropathic pain through activation of the lysophosphatidic acid (LPA)-1 receptor, possibly
via conversion to LPA by autotaxin (ATX).
Results: We examined in vivo LPA-induced LPA production using a biological titration assay with
B103 cells expressing LPA1 receptors. Intrathecal administration of LPC caused time-related
production of LPA in the spinal dorsal horn and dorsal roots, but not in the dorsal root ganglion,
spinal nerve or sciatic nerve. LPC-induced LPA production was markedly diminished in ATX
heterozygotes, and was abolished in mice that were deficient in LPA3, but not LPA1 or LPA2
receptors. Similar time-related and LPA3 receptor-mediated production of LPA was observed
following intrathecal administration of LPA. In an in vitro study using spinal cord slices, LPA-induced
LPA production was also mediated by ATX and the LPA3 receptor. Intrathecal administration of
LPA, in contrast, induced neuropathic pain, which was abolished in mice deficient in LPA1 or LPA3
receptors.
Conclusion: These findings suggest that feed-forward LPA production is involved in LPA-induced
neuropathic pain.
Background
Lysophosphatidylcholine (LPC, lysolecithin) is the most
abundant lysophospholipid in the blood and tissues
[1,2]. LPC, an important biologically active signaling mol-
ecule, is generated under specific physiological and path-
ological conditions, and exerts multiple effects in
atherosclerosis and inflammatory diseases [3-9]. LPC is
widely reported to possess demyelinating properties, and
has been used to study the processes underlying demyeli-
nation and remyelination [10-15]. Moreover, recent evi-
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dence suggests that LPC has an effect on pain. Topical LPC
treatment was found to induce painful sensory phenom-
ena (allodynia and hyperalgesia), focal demyelination
and changes in the expression of some pain-related mole-
cules [16]. These LPC-induced effects on pain transmis-
sion are similar to the reported effects of lysophosphatidic
acid (LPA), since LPA1 receptor signaling initiates neuro-
pathic pain and its underlying mechanisms, including
demyelination, and alters the expression of pain-related
molecules [17-19]. We speculate that centrally adminis-
tered LPC may be converted to LPA by autotaxin (ATX)
and cause LPA1 receptor activation. In accord with this
proposal, we recently demonstrated that neuropathic pain
induced by intrathecally (i.t.) administered LPC was abol-
ished in mice deficient in LPA1 receptors (Lpar1-/-mice),
and markedly attenuated in ATX gene heterozygous
mutant (atx+/-) mice [20,21]. Furthermore we demon-
strated that intense stimulation of spinal cord slices with
pain transmitters or capsaicin, which is thought to release
pain transmitters, caused a biosynthesis of LPC. This LPC
was subsequently converted to LPA in the presence of
recombinant ATX (rATX) [22]. These findings suggest that
neuropathic pain induced by i.t. administered LPC occurs
after its conversion to LPA and subsequent activation of
LPA1 receptor signaling. The present study was an initial
neurochemical examination of the processes underlying
LPC-induced LPA production, and provides evidence of
feed-forward LPA production through the LPA3 receptor.
Methods
Animals
Male C57BL/6J mice (Tagawa experimental animal labo-
ratory, Japan), heterozygous mutant mice for the ATX
gene (atx+/-) [23], and homozygous mutant mice for the
LPA1 [24], LPA2 [25] and LPA3 [26] receptor genes (Lpar1-
/-, Lpar2-/- and Lpar3-/-), and their sibling wild-type (WT)
mice from the same genetic background were used in this
experiment, unless stated otherwise. The subjects weighed
20-24 g. They were kept in a room maintained at 21 ±
2°C, 55 ± 5% relative humidity and a 12 h light/dark cycle
and had free access to a standard laboratory diet and tap
water. The procedures were approved by the Nagasaki
University Animal Care Committee, which complied with
the fundamental guidelines for proper conduct of animal
experiments and related activities in academic research
institutions under the jurisdiction of the Ministry of Edu-
cation, Culture, Sports, Science and Technology, Japan.
Drugs
LPC (18:1), LPA (18:1) and sphingosine-1-phosphate
(S1P) were purchased from Sigma (MO, USA). LPC and
LPA were dissolved in artificial cerebrospinal fluid (aCSF:
NaCl 125 mM, KCl 3.8 mM, KH2PO4 1.2 mM, NaHCO3
26 mM, glucose 10 mM) when they were used in vivo. In
the in vitro experiments, LPA and S1P were dissolved in
Dulbecco's Modified Eagle's Medium (DMEM) with 0.1%
fatty acid-free bovine serum albumin (A-6003 Sigma-
Aldrich, St. Louis, MO, USA).
Recombinant ATX
In accord with previous experiments involving rat pro-
teins [27], mouse cDNA for ATX was introduced into the
baculovirus transfer vector pFASTBac-1 (Invitrogen,
Carlsbad, CA, USA), and recombinant baculovirus was
prepared according to the manufacturer's protocol. After
purification using a baculovirus system and nickel col-
umn chromatography (HisTrap HP; Amersham Bio-
sciences, Osaka, Japan), rATX was obtained from 1 L of
culture supernatant of Sf9 insect cells infected with ATX
recombinant baculovirus.
Sample preparation from tissues
At different time-points (see Results for details) after the
injection of LPC or LPA, mice were anesthetized by pento-
barbital (50 mg/kg, i.p.). The bilateral dorsal horn (Lam-
ina I-V) of the lumbar (L4-6) spinal cord (SC), L4-6 dorsal
roots (DR), L4-6 dorsal root ganglions (DRG), L4-6 spinal
nerves (SPN) and L4-6 sciatic nerves (SCN) were then
removed to enable the extraction of LPA, as shown in Fig.
1a. The average wet weights of isolated bilateral SC, DR,
DRG, SPN and SCN in each mouse were 8, 4, 4, 4 and 5
mg, respectively. Following isolation, these tissue samples
were put into polypropylene 1.5 mL tubes and homoge-
nized by sonication in 300 μL serum-free DMEM solution
for approximately 30 sec. To extract LPA from the
homogenates using the solid-phase lipid extraction
method, the sample was then slowly loaded onto Oasis
HLB cartridges (Millipore, Tokyo, Japan), which had been
pre-conditioned with 3 mL of methanol, followed by 3
mL of distilled water. The column was washed with 3 mL
of distilled water then 1 mL of chloroform. LPA was then
eluted with 600 μL methanol and dried up with N2 gas.
The final sample was dissolved with 100 μL of DMEM
solution and stored at -80°C until the biological assay.
Biological titration method
B103 cells expressing LPA1 receptors and enhanced green
fluorescence protein [B103 (+) cells] were used for the
quantitative measurement of LPA, according to a method
[22] modified from the earlier report [28]. The cells were
maintained as monolayer cultures on tissue culture dishes
in DMEM supplemented with a 10% heat-inactivated fetal
bovine serum (Gibco, Carlsbad, CA, USA) that included
penicillin and streptomycin (final concentration 100
units/mL). Cells were seeded at 2.5 × 104 cells/cm2 onto 8-
well slide glass coated with poly-L-lysine (Sigma, MO,
USA; final concentration 100 mg/L) and collagen (BD
Bioscience, San Jose, CA, USA; final concentration 5 μg/
cm2). Next, they were cultured in DMEM containing 10%
heat-inactivated fetal bovine serum at 37°C in a 5% CO2Molecular Pain 2009, 5:64 http://www.molecularpain.com/content/5/1/64
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atmosphere for 10 h. Cells were then cultured in serum-
starved DMEM for 15 h, in accord with a previous study
[22].
In the biological assay, either standard LPA or a diluted
tissue sample was applied to B103 (+) cells. After incuba-
tion for 20 min at 37°C, the medium was replaced by 4%
paraformaldehyde and incubated for another 60 min at
25°C. The slide glass was then cover-slipped with Fluoro-
mount™ (DBS, Pleasanton, CA, USA) and examined
under a fluorescence microscope (Keyence, Osaka, Japan).
The percentage of cells that exhibited a rounded morphol-
ogy was determined in at least 500 cells in each well.
Preparation of spinal cord slices
Mice were anesthetized using pentobarbital (50 mg/kg,
i.p.) with 1% xylocaine. The lumbar spinal cord was
removed within 5 min and placed in ice-cold Krebs buffer
(117.0 mM NaCl, 3.6 mM KCl, 1.2 mM NaH2PO4, 1.2
mM MgCl2, 25.0 mM NaHCO3, 5.0 mM CaCl2 and 11.0
mM glucose) containing EGTA (1 mM), and aerated with
95% O2 and 5% CO2 (carbogen) at pH 7.4. After the
meninges were carefully removed, the rostral end of the
lumbar spinal cord was glued and supported by a block of
agar (1%). Transverse slices (500 μm) were then prepared
in Krebs buffer, under a controlled temperature of 4°C
and constant aeration with carbogen. Cutting was per-
formed using a super microslicer ZERO (DSK, Kyoto,
Japan) equipped with a ceramic knife. After sectioning,
the slices were washed with Krebs buffer and serum-
starved DMEM. Ten slices were then incubated in 100 μl
of serum-starved DMEM in 96-well culture dishes at 37°C
in 5% CO2 for 30 min. Just before drug treatment, 50 μl of
medium was removed. 50 μl of each drug at double the
final concentration was then added to each well. After
incubation, the culture medium was collected and filtered
using a nylon filter net (NRS-100; 13-XX, 100 μm pore;
Nippon Rikagaku Kikai, Tokyo, Japan) to remove any
fragments of spinal cord tissue. Half of each culture
medium was used in the experiments evaluating the cell
rounding effects.
Nociceptive tests
In thermal paw withdrawal tests, nociception was meas-
ured as the latency to paw withdrawal evoked by exposure
to a thermal stimulus [29,30]. Unanesthetized animals
were placed in Plexiglas cages on top of a glass sheet and
were allowed an adaptation period of 1 h. A thermal stim-
ulator (IITC Inc., Woodland Hills, CA, USA) was posi-
tioned under the glass sheet and the focus of the
projection bulb was aimed precisely at the middle of the
plantar surface of the animal. A mirror attached to the
stimulator permitted visualization of the plantar surface.
A cut-off time of 20 sec was set in order to prevent tissue
damage. The paw pressure test was performed, as
described previously [30]. Mice were placed into a Plex-
iglas chamber on a 6 × 6 mm wire mesh grid floor and
allowed to acclimatize for a period of 1 h. A mechanical
stimulus was then delivered onto the middle of the
plantar surface of the right hind-paw using a Transducer
Indicator (Model 1601, IITC Inc., Woodland Hills, CA,
USA). The pressure needed to induce a flexor response was
defined as the pain threshold. All behavioral experiments
were performed under double blind conditions.
RT-PCR
The expression levels of LPA receptors in SC and DR were
evaluated by reverse transcription polymerase chain reac-
Lysophosphatidylcholine (LPC) induces lysophosphatidic acid  (LPA) production in the spinal dorsal horn and dorsal roots Figure 1
Lysophosphatidylcholine (LPC) induces lysophospha-
tidic acid (LPA) production in the spinal dorsal horn 
and dorsal roots. (a) The exact regions of removed sam-
ples, including dorsal horn of lumbar spinal cord (SC), dorsal 
roots (DR), dorsal root ganglions (DRG), spinal nerves (SPN) 
and sciatic nerves (SCN). (b and c) Quantification of LPA 
production at different time points after the LPC treatment. 
The capital letter "C" showed on the time course axis repre-
sents the vehicle group. (d) LPC-induced LPA production in 
different preparations from SC, DR, DRG, SPN and SCN at 1 
and 3 h post-treatment. The measurement of LPA was car-
ried out in triplicate of each sample. All data represent the 
mean ± SEM from three separate experiments. Rounding 
morphology was evaluated in at least 500 enhanced green flu-
orescence-positive cells. *p < 0.05 compared with the vehicle 
group.Molecular Pain 2009, 5:64 http://www.molecularpain.com/content/5/1/64
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tion (RT-PCR), according to described method [31]. The
L4-6 SC and DR were removed from naïve mice and lysed
with TRIzol (Invitrogen, Carlsbad, CA, USA) for RNA
preparation. Total RNA (1 μg/sample) was used for cDNA
synthesis with PrimeScript® RT reagent Kit (Takara, Otsu,
Japan). A 1: 3 dilution series of the products was ampli-
fied by PCR. The cycling conditions for all primers were 3
min at 95°C, then 33 cycles of 30 s at 95°C, 30 s at 55°C
and 2 min at 72°C. The glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA was used as a control.
The PCR primer sequences were as follows: LPA1, 5'-AT
CTTTGGCTATGTTCGCCA-3' (forward) and 5'-TTGCTGT-
GAACTCCAGCCA-3' (reverse); for LPA2, 5'-TG GCCT AC
CTCTTCCTCATGTTCCA-3' (forward) and 5'-GTGT CC
AGCACACCACAAATGCC-3' (reverse); for LPA3, 3'-TTGC
CTCTGCAACATCTCGG-3' (forward) and 5'-CAT GACG-
GAGTTGAGCAGTG-3' (reverse); and for GAPDH, 5'-CA
AGGTCATCCATGACAACTTTG-3' (forward) and 5'-GG
CCATCCACAGTCTTCTGG-3' (reverse). Then, the PCR
products were analyzed by 1.5% agarose gel electrophore-
sis.
Statistical analysis
Statistical analysis was evaluated using the Student's t-test
and Tukey's multiple comparison post hoc analysis follow-
ing one-way ANOVA. The criterion of significance was set
at p < 0.05. All results are expressed as mean ± SEM.
Results
LPC induces LPA production in the spinal dorsal horn and 
dorsal roots
For the measurement of LPA production, we adopted a
biological titration method using LPA1 receptor-express-
ing B103 [B103 (+)] cells, according to the methods out-
lined in [28] and [22]. Using this method, we evaluated
the percentages of cells showing a rounded morphology
induced by the addition of LPA, examining at least 500
cells in each well. This measure was found to be specific to
LPA, since 100 nM (equivalent: 10 pmol/100 μl) of both
LPC [22] and S1P had no effect (Additional file 1, Fig.
S1a). In addition, 100 nM LPA and extracts from samples
produced no substantial effect on cell rounding in B103
cells without LPA1 receptor [B103 (-)] cells (Additional
file 1; Fig. S1b). In B103 (+) cells, a linear equation of the
induction of cell rounding activity was established for LPA
from 0.15 to 5 pmol, after subtracting the basal cell
rounding activity. Experiments were carried out in 100 μl
wells. The equation was defined as y = 5.454x + 5.66 (R2
= 0.991; x: log10 [LPA (pmol)]; y: cell rounding percent-
age; Additional file 1; Fig. S1c). In subsequent studies, LPA
equivalents in the extracts from the dorsal horn of the spi-
nal cord or dorsal roots were estimated using this equa-
tion based on linear LPA concentration-dependent
responses.
The basal level of LPA-equivalents in the spinal dorsal
horn (SC) of control mice was 0.66 pmol/mg tissue. The
LPA levels were markedly increased when mice were i.t.
injected with 1 nmol of LPC. The increase was maximal
(117 pmol/mg tissue) at 3 h, slightly declined at 5 h, and
had disappeared by day 1 (Fig. 1b). An increase in LPC-
induced LPA was observed with a similar time-course in
dorsal root (DR) preparations. The maximum level was
181 pmol/mg tissue (Fig. 1c), which was significantly
higher than that in the dorsal horn. As the isolated SC
(Lamina I-V) and DR (L4-6) weighed 8 and 4 mg respec-
tively, the level of LPA production was approximately 936
pmol for SC and 724 pmol for DR at 3 h after treatment
(117 pmol/mg tissue × 8 mg = 936 pmol; 181 pmol/mg
tissue × 4 mg = 724 pmol). Therefore, the total synthesis
of LPA is likely to have been at least 1.66 nmol (936 pmol
+ 724 pmol), which is higher than the original level of
LPC at 1 nmol. A similarly high level of LPA was also
observed at 5 h post-treatment. In contrast, no significant
increase in LPA levels was observed in the preparations of
DRG, SPN or SCN, as shown in Fig. 1d. In addition, there
were no significant differences in the basal level of LPA
equivalents among any of these preparations (Fig. 1d).
ATX and LPA3 receptors are required in LPC-induced LPA 
production
LPC-induced LPA production in the SC and DR was atten-
uated in atx+/- mice at 1 h after LPC treatment, compared
with WT mice (Fig. 2a). As expected, the LPA level in SC
and DR of atx+/- mice was decreased to 38 and 50% of con-
trol (WT) mice, respectively, suggesting that LPC is con-
verted to LPA by the action of endogenous ATX. However,
the level in WT mice was markedly increased to approxi-
mately 117 and 181 pmol/mg protein in the SC and DR
respectively, as long as 3 h after the LPC treatment. Since
the LPA level at 1 h was approximately 6 and 11 pmol/mg
proteins in the SC and DR respectively, time-dependent
changes were calculated as a 20-fold increase in the SC,
and a 16-fold increase in the DR (Fig. 2b). Interestingly,
the LPA levels in the SC and DR of atx+/- mice at 3 h were
both below 4% of WT mice (Fig. 2b), while LPC-induced
LPA production in the SC and DR was completely absent
in Lpar3-/- mice, but not in Lpar1-/- or Lpar2-/- mice (Fig. 2c
and 2d). On the other hand, three kinds of LPA1, LPA2 and
LPA3 receptors were all expressed in SC and DR by RT-
PCR, though the level of LPA1 transcripts was much higher
than the others (Additional file 2; Fig. S2).
LPA induces LPA production through LPA3 receptor in the 
spinal dorsal horn and dorsal roots
When 1 nmol LPA was i.t. injected, the LPA level in the SC
was increased in a time-dependent manner. A significant
increase was observed at 2 h, with a maximum level at 3
h, followed by a slight decline at 5 h. The maximum levelMolecular Pain 2009, 5:64 http://www.molecularpain.com/content/5/1/64
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at 3 h (approximately 100 pmol/mg protein) was equiva-
lent to that observed with LPC at 1 nmol (i.t.), as shown
in Fig. 3a. Similar levels were observed in the DR (Fig. 3b).
Calculations using the method described above suggest
that the total level of LPA [100 pmol/mg tissue × 8 mg
(SC) + 193 pmol/mg tissue × 4 mg (DR) = 1572 pmol]
was higher than the LPA level at 1 nmol. LPA-induced LPA
production was also entirely absent in Lpar3-/- mice (Fig.
3c and 3d).
In vitro evidence for LPA-induced LPA production through 
ATX and LPA3 receptors
Ten transverse slices of the lumbar spinal cord were cut
and washed using Krebs buffer several times to remove
cerebrospinal fluids (CSF), which contain high levels of
ATX [22,32]. These slices were incubated in serum-starved
DMEM for 30 min at 37°C, followed by LPA application
for the indicated time periods, with or without rATX. The
supernatant culture medium was then collected from
these cultured spinal cord slices. After filtration, the col-
lected medium was applied to B103 (+) cells for 20 min at
37°C, and LPA activity was evaluated (Fig. 4a). In the
presence of rATX (30 ng/mL), the addition of LPA at 0.1
pmol increased the LPA level in a time-dependent manner
from 30 to 60 min, followed by a slight decline (Fig. 4b).
However, no significant increase was observed in the
absence of rATX. In addition, LPA-induced LPA produc-
tion in the presence of rATX was significantly decreased in
Lpar3-/- mice, but not in Lpar1-/- or Lpar2-/- mice (Fig. 4c).
As the ATX-dependent LPA production was detected in the
supernatant of spinal cord slices in the present in vitro
assay, it appears that this synthesis occurs in the extracel-
lular space.
LPA1 and LPA3 receptors are required in LPA-induced 
hyperalgesia and allodynia
LPA i.t. injection (1 nmol) in WT mice caused robust ther-
mal hyperalgesia and mechanical allodynia for at least 7
days, while aCSF injection produced no change in thresh-
olds (Fig. 5). These findings are consistent with our previ-
ous report [17]. LPA-induced hyperalgesia and allodynia
were completely absent in Lpar1-/- and Lpar3-/- mice at days
3, 5, and 7 after injection (Fig. 5).
Discussion
Here we demonstrated for the first time that i.t. injected
LPC is not only converted to LPA through an action of
endogenous ATX, but also causes a new synthesis of LPA
in vivo in a feed-forward manner through the LPA3 recep-
tor. Previous studies examining the involvement of
ATX and LPA3 receptors are required for LPC-induced LPA  production Figure 2
ATX and LPA3 receptors are required for LPC-
induced LPA production. (a and b) Quantification of LPA 
production by LPC-treated tissue extraction from the SC 
and DR of wild-type (WT) mice and ATXgene heterozygous 
mutant (atx+/-) mice at 1 (panel a) and 3 h (panel b) post-
treatment. (c and d) LPC-induced LPA production in the SC 
(panel c) and DR (panel d) from WT, Lpar1-/-, Lpar2-/- and 
Lpar3-/- mice at 3 h post-treatment. Three female atx+/- mice 
were used in this experiment, but no significant difference 
was observed compared with other male mice. *p < 0.05 
compared with the WT group. Other details are shown in 
the legend of Figure 1.
LPA induces amplified LPA production through LPA3 recep- tor in spinal dorsal horn and dorsal roots Figure 3
LPA induces amplified LPA production through LPA3 
receptor in spinal dorsal horn and dorsal roots. (a and 
b) Time course of LPA production induced by LPA-treated 
tissue extraction from SC and DR. The capital letter "C" 
showed on the time course axis represents the vehicle 
group. (c and d) LPA3 receptor-dependent LPA production 
by LPA treatment. *p < 0.05 compared with the vehicle or 
WT group. Other details are shown in the legend of Figure 1.Molecular Pain 2009, 5:64 http://www.molecularpain.com/content/5/1/64
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endogenous ATX reported that it is a crucial enzyme for
the conversion of LPC to LPA [21,33-36], and that high
levels of ATX are expressed in CSF [22,32]. In this study,
we used a biological titration assay, in which LPA1 recep-
tor-mediated cell rounding activity was measured as a
quantitative evaluation of LPA levels in processed extracts
from tissue samples. In this assay, LPA concentration was
detectable from 0.15 pmol (equivalent: 1.5 nM). This
demonstrates the higher sensitivity of this assay compared
with the enzymatic cycling method, another widely used
method for LPA determination that is only suitable for
concentrations over 100 nM LPA [37]. Furthermore, the
addition of S1P to B103 (+) cells, and the addition of LPC
or LPA to B103 (-) cells did not significantly increase cell
rounding. Considering these findings together, the
present biological assay method appears to be useful for
the quantitation of low levels of LPA in extracts, as previ-
ously reported [22,28]. Because the addition of LPC to
B103(+) cells did not cause cell rounding activity [22], the
increase in LPA levels in the SC and DR after i.t. LPC injec-
tion is likely to be caused by the synthesis of new LPA. The
lack of LPA production in the DRG, SPN or SCN may be
simply related to the topological distance from the injec-
tion site of LPC. Since there are several subspecies of LPA
[38,39], however, the advanced method for measurement
of each species of LPA molecules utilizing mass spectrom-
etry including highly efficient purification and condensa-
tion would be the next subject.
The LPA level in atx+/- mice, which have been found to
express only 50% of both the ATX levels and the lysophos-
pholipase D (lyso-PLD) activity of WT mice [23], was just
LPA induces ATX-mediated LPA production through the  LPA3 receptor in vitro Figure 4
LPA induces ATX-mediated LPA production 
through the LPA3 receptor in vitro. (a) Schematic repre-
sentation of the method used. Details are described in the 
text. (b) Quantification of LPA production by LPA (0.1 
pmol)-treated culture media with or without recombinant 
ATX (rATX, 30 ng/ml). The capital letter "C" showed in the 
time course axis represents the vehicle group. (c) LPA3 
receptor-dependent LPA production by LPA and rATX. All 
data represent the mean ± SEM from three to seven separate 
experiments. *p < 0.05 compared with the vehicle or WT 
group. Other details are shown in the legend of Figure 1.
LPA1 and LPA3 receptors are involved in LPA-induced neuropathic pain Figure 5
LPA1 and LPA3 receptors are involved in LPA-induced neuropathic pain. LPA (1 nmol) or aCSF was i.t. injected, and 
the thermal paw withdrawal test (panel a) and paw pressure test (panel b) were performed at days 3, 5 and 7 after injection. 
Results represent the threshold of latency (s) or pressure (g) to thermal (a) or mechanical (b) stimulus, respectively. All data 
represent the mean ± SEM from 3 mice. *p < 0.05 compared with the aCSF group.Molecular Pain 2009, 5:64 http://www.molecularpain.com/content/5/1/64
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half that of the WT mice at 1 h following LPC injection.
These findings suggest that the rapid production of LPA
can be attributed to the ATX-mediated conversion of LPC
to LPA. Although the experiment using the ATX inhibitor
may support this hypothesis, commercially available ATX
inhibitor has some affinities to LPA1, LPA2  and LPA3
receptors.
A second important issue is the time-dependent increase
in LPA levels caused by injections of LPA as well as LPC.
I.t. injection of LPA (1 nmol) caused a time-dependent
increase in LPA levels in the SC and DR that lasted until 3
h post-treatment, followed by a slight decline in LPA lev-
els at 5 h. This decline may be caused by the product-inhi-
bition of ATX, since ATX activity is inhibited by high levels
of LPA [40]. LPA-induced LPA production was also
observed in the presence, but not in the absence of ATX in
the  in vitro experiment using spinal cord slices. LPA-
induced production of LPA has also been previously
found in an in vitro study using ovarian cancer cells. It was
reported that phosphatidylcholine was first converted to
phosphatidic acid (PA) by phospholipase D (PLD) fol-
lowed by further hydrolysis to LPA by phospholipase A
(PLA2) [41]. This finding of LPA production independent
of ATX in ovarian cancer cells may suggest the existence of
a different type of LPA synthetic pathway to that found in
the central nervous system in the present study.
A similar level and time-course of LPA synthesis was
observed following LPC injection (1 nmol, i.t.). The LPA
synthesis induced by LPC in both the SC and DR was
reduced to the basal level by 1 day and remained at this
level for the succeeding days, possibly because of degrada-
tion and diffusion. It should be noted that LPA produc-
tion induced by LPC markedly increased with time, until
3 h had passed. In contrast, the increase observed in atx+/-
mice was severely limited, suggesting that LPC-induced
LPA production largely depends on the ATX action in vivo.
This fact may be explained by the possibility that the LPA
converted from LPC by ATX causes a new synthesis of LPC
and this cycle occurs several times over 3 h.
Finally, it should be noted that LPA-induced de novo LPC
(or converted LPA) synthesis in SC and DR was com-
pletely absent in Lpar3-/- mice, but not in Lpar1-/- and
Lpar2-/- mice, though LPA1, LPA2 and LPA3 receptors were
all expressed in SC and DR. This finding was observed in
both in vivo and in vitro experiments using spinal cord sec-
tions, and was subsequently supported by nociceptive
tests showing that LPA-induced thermal hyperalgesia and
mechanical allodynia were absent in Lpar3-/- mice. This
result is consistent with previous reports suggesting that
LPA2 and LPA3 receptors might contribute to LPA-induced
LPA production in ovarian cancer cells, because ovarian
cancer cells express high levels of LPA2 and LPA3 receptors
whereas normal ovarian epithelial cells express low levels
of LPA2 and LPA3 receptors [41-43]. However, it is cur-
rently unclear which cell types in the spinal cord are
involved in LPA production. It is particularly difficult to
clarify whether the new synthesis of LPA occurs in specific
neurons or in highly differentiated cell types. Alterna-
tively, LPA synthesis may occur through neuron-glia inter-
actions as well as in an autocrine manner. In the present
study, we found that the LPA3 receptor is responsible for
LPA synthesis. According to previous reports, the LPA3
gene in mice is expressed in astrocytes, but not microglias
[44-46]. There are currently no reports detailing the
expression of the LPA3 receptor in mouse neurons. An
important aim of future research will be evaluating the
role of LPA3-related molecular mechanisms of LPA-
induced LPA production in single or co-cultured specific
cell types.
The present findings can also be considered in relation to
the mechanisms underlying neuropathic pain. In a series
of studies, we have demonstrated that LPA1 receptor sign-
aling initiates nerve injury- or LPA -induced (via i.t. injec-
tion) neuropathic pain and its underlying mechanisms.
These mechanisms include up-regulation of the expres-
sion of the voltage-gated calcium channel α2 δ-1 subunit
(Caα2δ-1) in the DRG, protein kinase Cγ (PKCγ) in the
spinal dorsal horn and demyelination of dorsal root fibers
as well as Aβ-fiber-mediated spinal reorganization [17-
19,47,48]. Most recently, a pharmacological study has
shown that LPA1 signaling within a 3 h timeframe can
cause neuropathic pain [49]. As such, it is reasonable to
speculate that the LPA1 and LPA3 receptors have differen-
tial key roles in the biological processes underlying the
mechanisms of neuropathic pain and the amplification of
LPA production, respectively.
Conclusion
Our study provides the first demonstration that LPA can
induce feed-forward LPA synthesis, a result that emerged
in both in vivo and in vitro experiments. This feed-forward
synthesis involves ATX-mediated conversion of LPC to
LPA and LPA3 receptor-mediated LPC production. These
mechanisms appear to be repeatedly active in a relatively
short period within 3 to 5 h. This result is consistent with
previous findings that LPA is a key molecule in the initia-
tion of mechanisms underlying neuropathic pain.
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